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Association of VAV2 and VAV3 
polymorphisms with cardiovascular 
risk factors
Nuria Perretta-Tejedor1,2,3, Javier Fernández-Mateos3,4, Luis García-Ortiz1,3,5, 
Manuel A. Gómez-Marcos1,3,5, José I. Recio-Rodríguez1,3,5, Cristina Agudo-Conde1,3,5, 
Emiliano Rodriguez-Sánchez3,5, Ana I. Morales1,3, Francisco J. López-Hernández1,2,3, 
José M. López-Novoa3,6, Rogelio González-Sarmiento3,4 & Carlos Martínez-Salgado1,2,3
Hypertension, diabetes and obesity are cardiovascular risk factors closely associated to the 
development of renal and cardiovascular target organ damage. VAV2 and VAV3, members of the  
VAV family proto-oncogenes, are guanosine nucleotide exchange factors for the Rho and Rac GTPase 
family, which is related with cardiovascular homeostasis. We have analyzed the relationship between 
the presence of VAV2 rs602990 and VAV3 rs7528153 polymorphisms with cardiovascular risk factors 
and target organ damage (heart, vessels and kidney) in 411 subjects. Our results show that being 
carrier of the T allele in VAV2 rs602990 polymorphism is associated with an increased risk of obesity, 
reduced levels of ankle-brachial index and diastolic blood pressure and reduced retinal artery caliber. 
In addition, being carrier of T allele is associated with increased risk of target organ damage in males. 
On the other hand, being carrier of the T allele in VAV3 rs7528153 polymorphism is associated with a 
decreased susceptibility of developing a pathologic state composed by the presence of hypertension, 
diabetes, obesity or cardiovascular damage, and with an increased risk of developing altered basal 
glycaemia. This is the first report showing an association between VAV2 and VAV3 polymorphisms with 
cardiovascular risk factors and target organ damage.
Hypertension (HT), diabetes mellitus (DM) and obesity are the most common risk factors associated to the devel-
opment of cardiovascular diseases1,2, the main cause of death worldwide3. HT is directly related to the incidence 
of cardiovascular complications (heart attack, ictus or peripheral arterial disease). Moreover, high blood pressure 
(BP) or DM together with other risk factor maximize their cardiovascular risk1. The presence of renal4, cardiac5 
and vascular6,7 target organ damage (TOD) also increases cardiovascular risk8. Vascular damage affects large and 
small vessels: Damage in large vessels is associated with atherosclerosis whereas damage in small vessels (narrow-
ing or blocked retinal blood vessels, macular edema) appears in disorders such as retinopathy, as reported in some 
studies which associate retinal vessels caliber with arterial hypertension9, left ventricular hypertrophy (LVH)10, 
metabolic syndrome11, cerebrovascular accident12 and coronary diseases13 and cardiovascular risk.
The guanine nucleotide exchange factors VAV2 and VAV3 are members of the VAV family of proto-oncogenes. 
Both are GDP-GTP dependent factors that stimulate Rho and Rac GTPases14, which have a similar structure, 
leading to the activation of intracellular pathways involved in cytoskeletal organization, transcriptomal dynam-
ics and other biological responses15. VAV proteins are expressed in a variety of tissues14,16 and in hematopoietic 
cells17 and participate in the development and function of hematopoietic lineage cells, lymphocytes, neutrophils, 
natural killers and osteoclasts15,18,19. All VAV family members contains an N-terminal calponin homology (CH) 
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domain, a catalytic Dbl-homology (DH) domain, an acidic (Ac) region, a pleckstrin-homology (PH) region, a C1 
subtype zinc finger (ZF) domain, a SH2 and a C-terminal SH3 (CSH3), a proline-rich region (PRR) and a more 
N-terminally-located SH3 (NSH3)14.
Sauzeau et al.20 analysed the effects of the absence of VAV2 in knock-out mice, which showed cardiovascular 
alterations such as cardiovascular remodeling, thickening of aorta media walls and LVH with fibrosis. In addition, 
these mice showed renal fibrosis, tachycardia and HT due to hyperstimulation of the renin/angiotensin/aldoster-
one axis and sympathetic nervous system20. They also observed a similar phenotype in VAV3−/− mice (cardiovas-
cular remodeling, HT, tachycardia, kidney and heart fibrosis)21, thus suggesting that both VAV2 and VAV3 play 
a key role in cardiovascular homeostasis20,21. On the other hand, Menacho-Marquez et al.22 have related VAV3 
with the metabolic syndrome and obesity, as VAV3−/− mice fed with chow diet developed metabolic syndrome, 
whereas these mice fed under fatty diets showed resistance against obesity and metabolic syndrome22.
Although several studies have observed that some single nucleotide polymorphisms (SNPs) in VAV genes 
are related to pathologies such as schizophrenia (VAV3 rs1410403)23, hypothyroidism (VAV3 rs4915077)24 and 
candidate genes for spontaneous glaucoma (VAV2 rs2156323 and VAV3 rs2801219)25- albeit later studies seem 
to rule out this involvement26, there are not studies relating VAV polymorphisms with cardiovascular risk. Thus, 
our aim is to analyze the relationship between VAV2 (rs602990) and VAV3 (rs7528153) polymorphisms with 
cardiovascular risk factors and TOD (heart, vessels and kidney) in a Spanish population8.
Results
We analyzed 411 subjects. Tables 1 and 2 summarize clinical, demographic and physical variables of the subjects 
under the study. The distribution of genotypes of VAV2 rs602990 and VAV3 rs7528153 polymorphisms in control 
samples are in Hardy-Weinberg equilibrium (Table 3).
There are statistically significant differences in the genotypic distribution for VAV2 rs602990 or VAV3 
rs7538153 polymorphisms in cardiovascular risk parameters such as the presence of cardiovascular risk factors, 
TOD, altered basal glycaemia or obesity.
On the one hand, there are statistically significant differences in the VAV3 rs7538153 genotypic distribution 
between the patients group (n = 281) and controls (n = 130). Being carrier of the T allele is associated with a 
decreased susceptibility of developing hypertension, diabetes, obesity or cardiovascular damage in the dominant 
model (Table 4). There are also significant differences in the genotypic distribution for VAV3 rs7538153 SNP 
between patients with (n = 51) and without altered basal glycaemia (n = 360). Being carrier of the T allele confers 
an increased risk of developing altered basal glycaemia in the recessive model (Table 5).
On the other hand, there are statistically significant differences in the allelic distribution for VAV2 rs602990 
polymorphism between males with TOD (n = 107) and controls (n = 93). Being carrier of the T allele is associ-
ated with an increased risk of TOD in the dominant model (Table 6). There are also differences in VAV2 rs602990 
SNP genotypic distribution between obese (BMI > 30) (n = 123) and non-obese (BMI 25–30) patients (n = 197) 
in the recessive model, where being carrier of the T allele is associated with an increased risk of obesity (Table 7) 
and a decreased average and minor retinal artery caliber (Table 8). Being carrier of the T allele in this SNP is also 
associated with low levels of DBP and low levels of right ABI (Table 8).
Discussion
Some polymorphic variants of genes involved in cardiovascular regulation seem to influence the risk or predis-
position to developing cardiovascular disease. For example, a nitric oxide synthase 3 (NOS3) polymorphism is 
related to rapid progression of heart failure in patients with dilated cardiomyopathy27. Moreover, polymorphic 
variants of the endothelial nitric oxide synthase (eNOS) gene are associated with coronary artery disease28. On 
the other hand, a paraoxonase 1 polymorphism is related with low-density lipoprotein cholesterol levels and with 
the risk of premature myocardial infarction, whereas another polymorphism of the same gene is associated with 
a positive family history of coronary artery disease29. Polymorphisms in angiotensinogen, angiotensin converting 
enzyme, angiotensin II type I receptor and aldosterone synthase, as well as polymorphisms in paraoxonase 2, 
NOS3 endothelin-1 and α and β -adrenergic receptors, are related to essential hypertension, myocardial stiffness 
and infarction, heart failure, coronary artery atherosclerosis, idiopathic dilated cardiomyopathy and left ventricle 
hypertrophy30.
Our study shows an association between VAV2 rs602990 and VAV3 rs7528153 polymorphisms with several 
cardiovascular risk factors and TOD (heart, vessels and kidney) in a Spanish population. Hypertension, diabetes 
and obesity are the most common cardiovascular risk factors1,2, closely associated to the development of cardi-
ovascular diseases, inducing renal and cardiovascular TOD1,8. VAV genes have been related with cardiovascular 
homeostasis20,21. Moreover, SNPs in VAV genes have been related with several diseases such as schizophrenia, 
hypothyroidism and glaucoma23–25. The SNP T298A VAV3 rs7528153 is located in the DH domain, which cata-
lyzes the activation of Rho and Rac GTPases31. There is an association between this VAV3 rs7528153 polymor-
phism and the presence of a pathologic state by the presence of hypertension, diabetes, obesity or cardiovascular 
disease (or combinations thereof), as T allele carriers of this SNP have a decreased risk of developing this patho-
logic state. VAV3−/− mice show cardiovascular alterations such as hypertension, tachycardia or cardiovascular 
remodeling21 and metabolic syndrome22 due to a chronic sympathetic excitation. In the ventrolateral medulla, a 
brainstem area that modulates respiratory, sympathetic and cardiovascular activities32, VAV3 acts regulating the 
conduction of axons of GABAergic neurons from the caudal to the rostral region33. The lack of VAV3 confers a 
reduced GABAergic transmission between these two areas leading to chronic sympathetic excitation33 and a vari-
ety of sympathetic mediated defects (cardiovascular defects, hypertension or tachycardia). Therefore, it is known 
that VAV3 has an important role contributing to proper axon guidance33 that are under the control of Rho/Rac 
family proteins34. Thus, we suggest that the SNP in the DH domain (rs7538153) confers an increased catalytic 
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N %
Sex
 Female 192 47.2
 Male 215 52.1
HT
 Yes 209 50.9
 No 202 49.1
Diabetes Mellitus
 Yes 66 83.5
 No 345 16.0
Pathologic state
 Yes 281 31.5
 No 130 68.0
Target organ damage
 Yes 191 46.2
 No 220 53.3
Altered basal glycaemia
 Yes 51 12.3
 No 360 87.2
BMI
 BMI < 25 74 17.9
 BMI 25–30 210 50.8
 BMI > 30 127 30.8
Dyslipidemia
 Yes 386 93.5
 No 24 5.8
Elevated PP
 Yes 97 23.5
 No 314 76.0
LVH
 Yes 34 8.2
 No 367 88.9
C-IMT
 Yes 73 17.7
 No 336 81.4
Altered PWV
 Yes 63 15.3
 No 343 83.1
PAD
 Yes 7 1.7
 No 402 98.3
CV risk
 < 1% 58 14.1
 1–5% 198 48.2
 5–10% 84 20.4
 > 10% 71 17.3
Antihypertensive drugs
 Yes 227 55.0
 No 184 44.6
Antidiabetic drugs
 Yes 66 16.0
 No 345 83.5
Lipid-lowering drugs
 Yes 164 39.7
 No 247 59.8
Table 1.  Characteristics of the 411 patients included in the study. BMI: body mass index; C-IMT: carotid 
intima media thickness; CV: cardiovascular; HT: hypertension; LVH: left ventricular hypertrophy; PAD: 
peripheral arterial disease; PP: pulse pressure; PWV: pulse wave velocity.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:41875 | DOI: 10.1038/srep41875
activity of Rho/Rac proteins in the GABAergic neurons, which contributes to a proper axon guidance and there-
fore a correct sympathetic activation.
We have found an association between VAV3 rs7528153 polymorphisms and altered basal glycaemia. Being 
carrier of the T allele is associated with increased risk of higher values of basal glycaemia. AMP-activated protein 
kinase (AMPK) acts as an upstream signal for VAV3 induction involving metformin-mediated signaling. Loss of 
VAV3 potentiates metformin-mediated glucose uptake, suggesting that VAV3 could become a molecular target 
for blood glucose regulation through AMPK35. We suggest that this SNP may affect the metformin-mediated 
glucose uptake through AMPK. In addition, as VAV3 is down-regulated in human pancreas with type 2 dia-
betes compared to healthy pancreas, this polymorphic variant of VAV3 may contribute to less severe diabetic 
neurophaties36.
Characteristics N Average SD
Weight. Kg 411 76.49 14.57
Age. years 411 60.31 9.79
BMI. Kg/m2 411 28.54 4.38
SBP. mmHg 411 133.84 17.18
DBP. mmHg 411 81.31 10.54
PP. mmHg 411 52.53 13.03
Heart rate. beats/min 411 70.11 10.97
ABI left 411 1.14 0.10
ABI right 410 1.13 0.10
Average C-IMT. mm 409 0.74 0.10
Maximun C-IMT. mm 409 0.90 0.12
PWV. m/s 406 8.64 1.61
VDP-Cornell. mV/ms 401 1548.23 565.01
Basal glycemia. mg/dL 411 95.60 28.10
Plasma creatinine. mg/dL 411 0.85 0.19
HDL-cholesterol. mg/dL 398 53.64 14.20
LDL- colesterol. mg/dL 403 132.09 34.32
Triglycerides. mg/dL 411 128.63 73.79
HbA1c. % 402 5.92 0.92
Hemoglobin. g/dL 407 15.09 1.17
Urinary creatinine. mg/dL 404 103.95 52.48
Microalbuminuria. mg/dL 403 13.14 65.61
Left artery. μ m 229 108.08 13.31
Right artery. μ m 234 109.04 12.57
Average artery. μ m 261 109.16 12.13
Minor artery. μ m 261 104.83 13.09
Left vein. μ m 229 141.42 19.07
Right vein. μ m 234 142.18 18.90
Average vein. μ m 261 142.29 17.89
Major vein. μ m 261 147.54 17.88
Left AVIx. μ m 190 0.79 0.11
Right AVIx. μ m 175 0.78 0.11
Average AVIx. μ m 259 0.78 0.08
Table 2.  Demographic, physical and basic analytical values of the patients included in the study. 
ABI = ankle brachial index; AVIx = arteriovenous index; BMI = body mass index; C- IMT = carotid intima 
media thickness; DBP = diastolic blood pressure; HbA1c = glycosylated hemoglobin; HDL = high-density 
lipoprotein; LDL = low-density lipoprotein; PP = pulse pressure; PWV = pulse wave velocity; SBP = systolic 
blood pressure; SD = standar deviation; VDP = voltage duration product. Artery, vein and AVIx values are 
retinal vessels.
Gene SNP ID Base Change SNP Chr location Assay ID HWE
VAV2 rs602990 1780 T > C p.Val594Met 9q34.1 C_2537403_10 > 0.05
VAV3 rs7528153 c.892 T > A Ser298Thr 1 C_447698_10 > 0.05
Table 3.  Characteristics of the VAV2 and VAV3 polymorphisms. Chr: chromosome; HWE: Hardy Weinberg 
equilibrium in control groups; SNP: single nucleotide polymorphism.
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The SNP V594M VAV2 rs602990 is located in the first SH3 domain. We detected an association between VAV2 
rs602990 polymorphisms and the presence of TOD. Being carrier of the T allele confers an increased risk of TOD 
in males (increased PP, HVI, IMT, PWV, ABI or microalbuminuria). Sauzeau et al. observed that VAV2−/− mice 
showed cardiovascular and renal alterations, such as remodeling in the cardiovascular system, LVH with fibrosis, 
interstitial renal fibrosis and lower glomerular filtration rate21 due to a chronic sympathetic excitation. In addi-
tion, double VAV2−/−, VAV3−/− and triple VAV1−/−, VAV2−/− and VAV3−/− mice showed defects in dendritic 
spine development, in axon transmission and synaptic plasticity in cortical, renal and hippocampal neurons due 
to deregulation of Rac activity37,38. We suggest that this SNP in the SH3 domain (which have a great affinity for 
proline rich sequences and recognize proteins in specific cell regions14) reduces the catalytic activity of VAV2 
(regulating Rac) in cortical, retinal an hippocampal neurons. Therefore, it produces a defect in axon guidance, 
which implicates a chronic sympathetic excitation as well as cardiovascular and renal alterations.
ABI index is an indicative parameter of peripheral arterial disease and a low ABI index is directly related with 
vascular damage1. According with our data, T allele in VAV2 rs602990 polymorphism is associated with low levels 
of right ABI, and therefore is associated with an increased risk of vascular damage. Moreover, T allele in VAV2 
rs602990 polymorphisms is also associated with an increased risk of obesity. On the other hand, the T allele in 
this VAV2 SNP is associated with reduced retinal artery caliber. Retinal arterial narrowing is associated with ret-
inal damage such as retinopathy. Several studies found a relationship between retinal vessels caliber with LVH10, 
metabolic syndrome11, cerebrovascular accidents12 and coronary diseases13.
Although Sauzeau et al. observed that VAV2−/− mice were hypertensive due to sympathetic excitation, some 
studies reported that Rac1 is involved in vasoconstriction39. Overexpression of Rac1 in smooth muscle cells in 
mice induces hypertension as it regulates the redox state of the blood vessels and blood pressure homeostasis 
through the NADPH oxidase pathway40. VAV2 is a guanosine nucleotide exchange factor which activates Rac1 
in many cell types41,18. In our study, we found that being carrier of the T allele in VAV2 rs602990 polymorphism 
is associated with lower levels of DBP, suggesting that this polymorphism confers less catalytic activity to VAV2, 
resulting in less activation of Rac 1 and therefore low DBP.
Overall, this study shows the association between some VAV2 and VAV3 polymorphisms with cardiovascular 
risk factors in a Spanish population. However, this study has some limitations. First, this is a retrospective study. 
Second, due to the number of analyzed patients, there is a limitation in the statistical power of the study. Thus, in 
order to confirm our results, studies should be done in a larger population.
In conclusion, this is the first study showing the association between VAV2 and VAV3 polymorphisms with 
cardiovascular risk factors and TOD, possibly through their influence in Rho and Rac pathways. These polymor-
phisms are associated with indicators frequently used in the clinical practice to evaluate cardiovascular damage 
(ABI, retinal artery thickness, DBP, basal glucose and integrated cardiovascular pathologic state). Thus, our study 
SNP Genotype
Pathological Non pathological
P value OR (95% CI)N % N %
VAV3 rs7528153
AA 144 53.9 47 38.5 Ref. 1.000
AT 94 35.2 62 50.8 0.002 0.484 (0.304–0.770)
TT 29 10.9 13 10.7 0.390 0.724 (0.346–1.514)
VAV3 rs7528153 dominant
AA 144 53.9 47 38.5 Ref. 1.000
AT + TT 123 46.1 75 61.5 0.004 0.526 (0.338–0.817)
VAV3 rs7528153 recessive
AA + AT 238 89.1 109 89.3 Ref. 1.000
TT 29 10.9 13 10.7 0.945 0.526 (0.338–0.817)
Table 4.  Distribution of VAV3 rs7528153 genotypes among patients with or without pathological state. 




P value OR (95% CI)
Yes No
N % N %
VAV3 rs7528153
AA 24 49.0 167 49.1 Ref. 1.000
AT 15 30.6 141 41.5 0.362 0.727 (0.367–1.442)
TT 10 20.4 32 9.4 0.068 2.169 (0.944–4.985)
VAV3 rs7528153 dominant
AA 24 49.0 167 49.1 Ref. 1.000
AT + TT 25 51.0 173 50.9 0.977 0.991 (0.543–1.807)
VAV3 rs7528153 recessive
AA + AT 39 79.6 308 90.6 Ref. 1.000
TT 10 20.4 32 9.4 0.024 2.481 (1.129–5.453)
Table 5.  Distribution of VAV3 rs7528153 genotypes among patients with or without altered basal 
glycaemia. P value & OR adjusted by sex and age. CI = confidence interval; OR = odd ratio; ref. = reference; 
SNP = single nucleotide polymorphism.
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suggests that the analysis of VAV2 and VAV3 polymorphisms might be a useful diagnostic and prognostic marker 
of susceptibility to cardiovascular damage.
Methods
This is a cross-sectional study performed in patients with or without DM and HT. 411 subjects aged between 20–80 
years were recruited in the Primary Care Research Unit of La Alamedilla Health Centre, Salamanca (Spain), cover-
ing a population of 46,000 inhabitants. HT was diagnosed when the mean of three different BP measurements was 
≥ 120 mm Hg for systolic blood pressure (SBP) or ≥ 80 mm Hg for diastolic blood pressure (DBP) or when patients 
received antihypertensive drugs. DM was diagnosed following 2 criteria: basal plasma glucose ≥ 126 mg/dL, glyco-
sylated hemoglobin (HbA1c) > 6,5% or when patients received antidiabetic drugs. Obesity was diagnosed by body 
mass index (BMI) ≥ 30 kg/m2 1. Dyslipidemia was considered when total cholesterol > 4.9 mmol/L (190 mg/dL) or low 
density lipoprotein cholesterol > 3 mmol/L (115 mg/dL) or high-density lipoprotein cholesterol: men < 1.0 mmol/L 
(40 mg/dL), women < 1.2 mmol/L (46 mg/dL) or triglycerides > 1.7 mmol/L (150 mg/dL). In this study we consider 
pathologic state when there is a diagnostic of HT, DM, obesity or cardiovascular disease (ischaemic stroke or cer-
ebrovascular disease). Exclusion criteria: patients unable to comply with the protocol requirement (psychological 
and/or cognitive disorders, failure to cooperate, educational limitations and problems in understanding written lan-
guage, and failure to sign the informed consent document), patients participating in a clinical trial or patients with 
serious comorbidities. Normotensive and normoglycemic patients with the above described exclusion criteria and 
without detectable renal and cardiovascular alterations were selected as controls.
TOD is a variable composed of renal TOD (assessed by microalbuminuria) vascular TOD (assessed by carotid 
intima-media thickness (IMT), pulse wave velocity (PWV) and ankle-brachial index (ABI)) and cardiac TOD 
(assessed by left ventricular hypertrophy (LVH) and pulse pressure (PP)).
Ethical and legal issues. The experimental protocol was in accordance with the Declaration of Helsinki 
(2008) of the World Medical Association, approved by the University Hospital of Salamanca Ethics Committee 
and complied with Spanish data protection law (LO 15/1999) and specifications (RD 1720/2007). An informed 
consent was obtained from all participants recruited in the study.
Anthropometric measurements. We calculated BMI (kg/m2) measuring body weight using a homologated 
electronic scale (Seca 70, Hamburg, Germany; precision ± 0.1 kg), and height with a portable system (Seca 222).
SNP Genotype
Target organ damage
P value OR (95% CI)
Yes No
N % N %
VAV2 rs602990
CC 19 17.8 31 33.3 Ref. 1.000
CT 63 58.9 40 43.0 0.026 2.253 (1.101–4.613)
TT 25 23.4 22 23.7 0.298 1.559 (0.675–3.598)
VAV2 rs602990 dominant
CC 19 17.8 31 33.3 Ref. 1.000
CT + TT 88 82.2 62 66.7 0.044 2.007 (1.018–3.956)
VAV2 rs602990 recessive
CC + CT 82 76.6 71 76.3 Ref. 1.000
TT 25 23.4 22 23.7 0.746 0.894 (0.454–1.760)
Table 6.  Distribution of VAV2 rs602990 genotypes among male patients with and without target organ 
damage. P value & OR adjusted by sex and age. CI = confidence interval; OR = odd ratio; ref. = reference; 
SNP = single nucleotide polymorphism.
SNP Genotype
Obesity
P value OR (95% CI)
Yes No
N % N %
VAV2 rs602990
CC 31 25.6 54 27.4 Ref. 1.000
CT 52 43.0 102 51.8 0.814 0.935 (0.533–1.639)
TT 38 31.4 41 20.8 0.109 1.679 (0.890–3.165)
VAV2 rs602990 dominant
CC 31 25.6 54 27.4 Ref. 1.000
CT + TT 90 74.4 143 72.6 0.603 1.149 (0.682–1.936)
VAV2 rs602990 recessive
CC + CT 83 68.6 156 79.2 Ref. 1.000
TT 38 31.4 41 20.8 0.036 1.753 (1.038–2.958)
Table 7.  Distribution of VAV2 rs602990 genotypes among obese (BMI > 30) and non-obese (BMI 25–30) 
patients. P value & OR adjusted by sex and age. CI = confidence interval; OR = odd ratio; ref. = reference; 
SNP = single nucleotide polymorphism.
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Plasma and urine determinations. We collected urine and blood samples in the morning after fast-
ing for at least 8 hours. We measured creatinine, basal glucose, HbA1c, triglycerides, high-density lipoprotein 
(HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol in plasma, and creatinine and microalbumin in 
urine using standard automatic techniques on a blind basis in the Biochemistry laboratory of the University 
Hospital, Salamanca (Spain).
Blood pressure determination. Office BP evaluation involved three measurements of SBP and DBP with a 
validated OMRON model M7 sphygmomanometer (Omron Health Care, Kyoto, Japan) following the recommen-
dations of the European Society of Hypertension (ESH)1. We calculated SBP, DBP, and PP with the mean values 
of the second and third measurements.
Evaluation of peripheral artery disease. We used the ankle–brachial index (ABI), in patients refrained 
from drinking coffee or smoking tobacco for at least 8 h before measurements and at 22–24 °C. With the patient 
lying in supine position and with the feet uncovered, we measured BP in the lower limbs after resting for 20 min 
using a portable Doppler system Minidop Es-100Vx (Hadeco Inc, Miyamae-ku Kawasaki, Japan). We calculated 
ABI automatically for each foot by dividing the higher of the two SBP in the ankle by the higher of the two SBP in 
the arm. An ankle–brachial index < 0.9 is considered abnormal1.
Determination of left ventricular hypertrophy. Electrocardiography (ECG) was performed with a 
General Electric MAC 3.500 ECG System (Niskayuna, New York, USA) that automatically measures wave voltage 
and duration and estimates the criteria of the Cornell voltage duration product (VDP)42 LVH was defined as a 
Sokolow-Lyon index > 3.5 mV; RaVL > 1.1 mV, Cornell VDP > 244 mV*ms or RaVL > 1.1 mV1.
Determination of pulse wave velocity. We evaluated PWV with the SphygmoCor System (AtCor 
Medical Pty Ltd, Head Office, West Ryde, Australia). We analyzed the pulse waves of the carotid and femoral 
arteries with the patient in the supine position measuring the delay with respect to the ECG wave, and then cal-
culating PWV. We obtained distance measurements with a measuring tape from the sternal notch to the carotid 
and femoral arteries at the sensor location.
Assessment of carotid intima-media thickness. We used a Micromax ultrasound device (SonoSite Inc, 
Bothell, WA) paired with a 5–10 MHz multifrequency high-resolution linear transducer with Sonocal software 
for performing automated measurements of carotid IMT in order to optimise reproducibility. We made measure-
ments of the common carotid after examination of a 10 mm longitudinal section at a distance of 1 cm from the 
bifurcation. We took measurements in the proximal wall, and in the distal wall in the lateral, anterior and poste-
rior projections, following an axis perpendicular to the artery to discriminate two lines: one for the intima-blood 
interface and the other for the media-adventitious interface. We took six measurements of both the right and 
left carotid arteries, using average values (average carotid IMT) and maximum values (maximum carotid IMT) 
automatically calculated by the software43. Average IMT was considered abnormal if > 0.90 mm or in the presence 
of atherosclerotic plaques with a diameter of 1.5 mm or a focal increase of 0.5 mm or 50% of the adjacent IMT1.
Evaluation of renal function. We assessed kidney damage measuring the estimated glomerular filtration 
rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)44 equation, the Modification of 
Diet in Renal Disease- Isotopic Dilution Mass Spectrometry (MDRD-IDMS)45 and proteinuria, as assessed by the 
albumin/creatinine ratio following the criteria of the 2013 European Society of Hypertension/European Society 
of Cardiology Guidelines1. We considered subclinical renal damage when glomerular filtration rate was below 
30–60 mL/min/1.73 m2 or microalbuminuria between 30–300 mg/24 h or albumin–creatinine ratio between 
30–300 mg/g, 3.4–34 mg/mmol. We defined renal disease as a glomerular filtration rate < 30 mL/min/1.73 m2, 
proteinuria > 300 mg/24 h or albumin/creatinine ratio > 300 mg/24 h1.
Evaluation of retinopathy. We evaluated retinography with a Topcon TRC NW 200 non-mydriatic retinal 
camera (Topcon Europe B.C., Capelle a/d Ijssel, The Netherlands), obtaining nasal and temporal images centered 
on the disk. Images were loaded into our own developed software, AV Index calculator (Ciclorisk SL, Salamanca, 
Spain, registry no. 00/2011/589), which automatically estimates the mean caliber of veins and arteries in millime-
tres as an arteriole– venule ratio, arteriovenous index (AVIx). An AVIx of 1.0 suggests that arteriolar diameters 
Characteristic
VAV2 average ± SD P value VAV2 dominant average ± SD
P value
VAV2 recessive average ± SD
P valueCC CT TT CCvsTT CCvsCT CTvsTT CC CT + TT CC + CT TT
DBP 83.01 ± 9.91 81.34 ± 10.73 79.28 ± 10.89 0.051 0.567 0.482 83.01 ± 9.91 80.61 ± 10.81 0.064 81.92 ± 0.61 79.28 ± 1.03 0.045
ABI right 1.13 ± 0.10 1.14 ± 0.09 1.11 ± 0.11 0.419 1.000 0.058 1.13 ± 0.10 1.13 ± 0.10 0.782 1.14 ± 0.10 1.11 ± 0.11 0.043
Retinal artery 
average 108.76 ± 11.07 111.19 ± 12.26 106.45 ± 13.43 0.988 0.454 0.035 108.76 ± 11.07 109.56 ± 12.39 0.609 110.33 ± 11.88 106.45 ± 13.43 0.028
Retinal artery 
minor 104.62 ± 11.14 106.74 ± 13.82 102.16 ± 14.18 1.000 0.747 0.076 104.62 ± 11.14 105.17 ± 14.08 0.733 105.99 ± 12.95 102.17 ± 14.18 0.043
Table 8.  Statistically significant results in the distribution of VAV2 rs602990 according to different 
cardiovascular characteristics measured on the patients. P value adjusted by age and sex. All data are corrected 
by Bonferroni post-hoc test. ABI = ankle-brachial index; DBP = diastolic blood pressure; SD = standard deviation.
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are on average the same as venular diameters in that eye, whereas a smaller AVR suggests narrower arterioles. The 
pairs of main vessels in the upper and lower temporal quadrants were used, rejecting all other vessels, to improve 
reliability and increase efficiency of the process, analysing measures for each quadrant separately and together to 
estimate the mean measure in each eye.
Cardiovascular risk assessment. We estimated cardiovascular risk (CVR) of morbidity and mortality 
using the 2013 guidelines of the ESH1, which stratify cardiovascular risk based on blood pressure, cardiovascu-
lar risk factors, asymptomatic organ damage and presence of diabetes, symptomatic cardiovascular disease or 
chronic kidney disease. The classification in low, moderate, high and very high risk is retained from previews 
guidelines and refers to the 10-year risk of cardiovascular mortality as defined by the 2012 ESC prevention guide-
lines 46, based in the SCORE scale, that classifies the cardiovascular risk in low (< 1%), moderate (1–5%), higher 
(5–10%), and very high risk (≥ 10%).
DNA isolation and genotyping. We extracted genomic DNA from peripheral blood leukocytes by the 
phenol-chloroform method47. We identified VAV2 rs602990 and VAV3 rs7528153 polymorphisms by the allelic 
discrimination assay with TaqMan® probes (Life Technologies, Carlsbad, California, USA) (Table 3) using spe-
cific oligonucleotides to amplify the regions containing the polymorphisms and two labelled probes with the 
fluorochromes VIC and FAM to detect both alleles of each polymorphism48. We performed the reaction with 
the Universal PCR Master Mix in the Real-Time PCR system of Step-One Plus (Applied Biosystems, Forster, 
California, USA). To ensure the reproducibility, a 5% of random samples were re-genotyped.
Statistical analysis. We used the statistical software SPSS v.21.0 (Armonk, New York, USA). We tested 
control group subjects for conformity to the Hardy-Weinberg equilibrium using the chi-squared test for each 
polymorphism. We analysed the association between the different clinical and molecular qualitative variables by 
cross tabs and the Pearson X2 test. The odds ratio (OR) and 95% confidence intervals were calculated by a logis-
tic regression model to evaluate the association with the risk to develop the disease. We compared quantitative 
variables and the influence of polymorphism distribution by the ANOVA test in those cases that followed a para-
metric distribution (Levene’s test for homogeneity of variances, p > 0.05). When data followed a non-parametric 
distribution, we applied a Mann Whitney U test. In order to consider confounding variables, we made a statistical 
adjustment by sex and the continuous variable of age. We considered statistically significant differences when 
P-value was < 0.05.
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